Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds

PSMA

  • A Phase II, Open-Label Study to Assess Safety and Management Change Using <sup>68</sup>Ga-THP PSMA PET/CT in Patients with High-Risk Primary Prostate Cancer or Biochemical Recurrence After Radical Treatment: The PRONOUNCED Study
    You have access
    A Phase II, Open-Label Study to Assess Safety and Management Change Using 68Ga-THP PSMA PET/CT in Patients with High-Risk Primary Prostate Cancer or Biochemical Recurrence After Radical Treatment: The PRONOUNCED Study
    Asim Afaq, Heather Payne, Reena Davda, John Hines, Gary J.R. Cook, Marie Meagher, Dimitrios Priftakis, Victoria S. Warbey, Anand Kelkar, Clement Orczyk, Anita Mitra, Sarah Needleman, Michael Ferris, Greg Mullen and Jamshed Bomanji
    Journal of Nuclear Medicine December 1, 2021, 62 (12) 1727-1734; DOI: https://doi.org/10.2967/jnumed.120.257527
  • Tumor Detection of <sup>18</sup>F-PSMA-1007 in the Prostate Gland in Patients with Prostate Cancer Using Prostatectomy Specimens as Reference Method
    You have access
    Tumor Detection of 18F-PSMA-1007 in the Prostate Gland in Patients with Prostate Cancer Using Prostatectomy Specimens as Reference Method
    Elin Trägårdh, Athanasios Simoulis, Anders Bjartell and Jonas Jögi
    Journal of Nuclear Medicine December 1, 2021, 62 (12) 1735-1740; DOI: https://doi.org/10.2967/jnumed.121.261993
  • PSMA PET for the Assessment of Metastatic Hormone-Sensitive Prostate Cancer Volume of Disease
    You have access
    PSMA PET for the Assessment of Metastatic Hormone-Sensitive Prostate Cancer Volume of Disease
    Francesco Barbato, Wolfgang P. Fendler, Isabel Rauscher, Ken Herrmann, Axel Wetter, Justin Ferdinandus, Robert Seifert, Michael Nader, Kambiz Rahbar, Boris Hadaschik, Matthias Eiber, Andrei Gafita and Manuel Weber
    Journal of Nuclear Medicine December 1, 2021, 62 (12) 1747-1750; DOI: https://doi.org/10.2967/jnumed.121.262120
  • You have access
    68Ga-PSMA PET/CT for response assessment and outcome prediction in metastatic prostate cancer patients treated with taxane-based chemotherapy
    Qaid Ahmed Shagera, Carlos Artigas, Ioannis Karfis, Gabriela Critchi, Nieves Martinez Chanza, Spyridon Sideris, Alexandre Peltier, Marianne Paesmans, Thierry Gil and Patrick Flamen
    Journal of Nuclear Medicine November 12, 2021, jnumed.121.263006; DOI: https://doi.org/10.2967/jnumed.121.263006
  • Matched-Pair Comparison of <sup>18</sup>F-DCFPyL PET/CT and <sup>18</sup>F-PSMA-1007 PET/CT in 240 Prostate Cancer Patients: Interreader Agreement and Lesion Detection Rate of Suspected Lesions
    You have access
    Matched-Pair Comparison of 18F-DCFPyL PET/CT and 18F-PSMA-1007 PET/CT in 240 Prostate Cancer Patients: Interreader Agreement and Lesion Detection Rate of Suspected Lesions
    Maurits Wondergem, Friso M. van der Zant, Wouter A.M. Broos and Remco J.J. Knol
    Journal of Nuclear Medicine October 1, 2021, 62 (10) 1422-1429; DOI: https://doi.org/10.2967/jnumed.120.258574
  • Rational Linker Design to Accelerate Excretion and Reduce Background Uptake of Peptidomimetic PSMA-Targeting Hybrid Molecules
    You have access
    Rational Linker Design to Accelerate Excretion and Reduce Background Uptake of Peptidomimetic PSMA-Targeting Hybrid Molecules
    Ann-Christin Eder, Martin Schäfer, Jana Schmidt, Ulrike Bauder-Wüst, Mareike Roscher, Karin Leotta, Uwe Haberkorn, Klaus Kopka and Matthias Eder
    Journal of Nuclear Medicine October 1, 2021, 62 (10) 1461-1467; DOI: https://doi.org/10.2967/jnumed.120.248443
  • SUVs Are Adequate Measures of Lesional <sup>18</sup>F-DCFPyL Uptake in Patients with Low Prostate Cancer Disease Burden
    You have access
    SUVs Are Adequate Measures of Lesional 18F-DCFPyL Uptake in Patients with Low Prostate Cancer Disease Burden
    Yves J.L. Bodar, Berend P.F. Koene, Bernard H.E. Jansen, Matthijs C.F. Cysouw, Dennie Meijer, N. Harry Hendrikse, André N. Vis, Ronald Boellaard and Daniela E. Oprea-Lager
    Journal of Nuclear Medicine September 1, 2021, 62 (9) 1264-1269; DOI: https://doi.org/10.2967/jnumed.120.260232
  • Detection of Early Progression with <sup>18</sup>F-DCFPyL PET/CT in Men with Metastatic Castration-Resistant Prostate Cancer Receiving Bipolar Androgen Therapy
    You have access
    Detection of Early Progression with 18F-DCFPyL PET/CT in Men with Metastatic Castration-Resistant Prostate Cancer Receiving Bipolar Androgen Therapy
    Mark C. Markowski, Pedro Isaacsson Velho, Mario A. Eisenberger, Martin G. Pomper, Kenneth J. Pienta, Michael A. Gorin, Emmanuel S. Antonarakis, Samuel R. Denmeade and Steven P. Rowe
    Journal of Nuclear Medicine September 1, 2021, 62 (9) 1270-1273; DOI: https://doi.org/10.2967/jnumed.120.259226
  • <sup>68</sup>Ga-PSMA-11 PET/CT Improves Tumor Detection and Impacts Management in Patients with Hepatocellular Carcinoma
    You have access
    68Ga-PSMA-11 PET/CT Improves Tumor Detection and Impacts Management in Patients with Hepatocellular Carcinoma
    Nader Hirmas, Catherine Leyh, Miriam Sraieb, Francesco Barbato, Benedikt M. Schaarschmidt, Lale Umutlu, Michael Nader, Heiner Wedemeyer, Justin Ferdinandus, Christoph Rischpler, Ken Herrmann, Pedro Fragoso Costa, Christian M. Lange, Manuel Weber and Wolfgang P. Fendler
    Journal of Nuclear Medicine September 1, 2021, 62 (9) 1235-1241; DOI: https://doi.org/10.2967/jnumed.120.257915
  • The Impact of Monosodium Glutamate on <sup>68</sup>Ga-PSMA-11 Biodistribution in Men with Prostate Cancer: A Prospective Randomized, Controlled Imaging Study
    You have access
    The Impact of Monosodium Glutamate on 68Ga-PSMA-11 Biodistribution in Men with Prostate Cancer: A Prospective Randomized, Controlled Imaging Study
    Wesley R. Armstrong, Andrei Gafita, Shaojun Zhu, Pan Thin, Kathleen Nguyen, Rejah Alano, Stephanie Lira, Kiara Booker, Linda Gardner, Tristan Grogan, David Elashoff, Martin Allen-Auerbach, Magnus Dahlbom, Johannes Czernin and Jeremie Calais
    Journal of Nuclear Medicine September 1, 2021, 62 (9) 1244-1251; DOI: https://doi.org/10.2967/jnumed.120.257931

Pages

  • Previous
  • Next
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • 14
SNMMI

© 2022 Journal of Nuclear Medicine

Powered by HighWire